Mentions
Extended reach
Total likes
Video views
AI synopsis
The overall narrative reveals a highly positive and optimistic attitude towards retatrutide, with posts citing impressive weight loss percentages and Phase 2 trial results from reputable sources like NEJM, using enthusiastic phrases such as 'game changer' and 'revolutionize' to underscore its transformative potential in obesity therapy. The tone and choice of words reflect a deep engagement with the scientific and future implications of this treatment.
Many posts express strong support and enthusiasm for the research findings, highlighting the drug's superior efficacy and potential to transform obesity treatment.
Posts demonstrate high engagement and curiosity, mentioning specific data points like 24% weight loss, comparisons to established drugs, and discussions about Phase 2 results.
Several discussions delve deeply into the mechanisms, side effects, and implications, with references to specific trial data, clinical implications, and future potential.
The discussions emphasize the significant clinical impact, with predictions that the drug could revolutionize obesity management and even lead to the obsolescence of older treatments, indicating high perceived importance.
Unfortunately, it likely won't be available for prescription in the U.S. until 2026 or 2027. Sources: https://t.co/uJ4iDywoXS https://t.co/TnCvBmiB9K
This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial https://t.co/jNL1GNnHPT #Endocrinology https://t.co/ZknpCo49ky
Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettiamo la fine della fase 3, i risultati preliminari sono però ottimi, con la dose massima i pazienti hanno perso il 25% del loro peso. https://t.co/pVRzXRoG80
איבוד של מסת השריר, איבוד של מסת השלד ואוסטאופורוזיס. מי שרוצה לקרוא עוד יש פה סקירה מרתקת: https://t.co/6cCWfySQB6 ומאמר הניסוי הקליני: https://t.co/UD1KGQCvbv
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight https://t.co/Yh0vGKq692 https://t.co/muHZgCtBpI
❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated significant advancement
This video breaks down the six most powerful fat loss peptides on the market, including how they work, research evidence, and ideal users. Discover peptides that enhance fat burning, suppress appetite, or boost…
This video exposes the harmful misinformation spreading about Ozempic online. It discusses the impact of marketing strategies, potential side effects, and shares simple, side effect-free hacks to enhance health…
A new drug achieves 24% body weight loss and improves blood pressure, glucose, triglycerides, and cholesterol. It is important to understand how retatrutide works and potential downsides, as these medications may…
Retatrutide, a triple-hormone receptor agonist, is tested for safety and efficacy in adults with BMI of 27+ in a 48-week phase 2 trial. Results demonstrated significant weight loss, with higher doses yielding greater…
IFBB Pro Big Paul explains the science behind Retatrutide, a triple-hormone receptor agonist, in a Phase 2 clinical trial. The drug demonstrates significant weight loss results, offering promising potential for obesity…
Retatrutide is a promising new Eli Lilly weight loss drug showing significant efficacy in phase 2 trials, with higher doses leading to greater weight loss at 24 and 48 weeks, and high achievement of weight loss…
New research examines retatrutide's impact on weight, fat loss, and body composition over 36 weeks, highlighting muscle preservation and effectiveness compared to other weight loss methods.
Peptides are gaining popularity with claims of fat loss, muscle growth, and healing. This video explains the most talked-about peptides, their research-backed benefits, risks, and the importance of FDA approval…
This phase 2 trial assesses the effectiveness and safety of retatrutide for obesity treatment. Significant weight loss was observed with higher doses, with participants achieving important weight reduction milestones…
Explore promising hair loss treatments including RU58841 and related solutions, with discounts available. Learn about effective options for hair regeneration and hair care products that may help reverse balding.
This episode provides an in-depth analysis of GLP-1 drugs like Ozempic and Wegovy, discussing safety concerns, side effects, lawsuits, and their impact on mental health and fat liberation debates. It also explores the…
【参照】 米イーライ・リリーCEO、「27年にも新型肥満症薬」 重症者の増加で - 日本経済新聞 https://t.co/M1frRXeEZz Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial https://t.co/NXe5kfaOFq
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial https://t.co/yw8QXwE0FA
@DevanSinha These are the data on discontinuation, from here (https://t.co/9YSBz304Lc) (I'm not sure whether that answers the question?) https://t.co/3mWZZlqkLs
Sources: https://t.co/uJ4iDyvR8k https://t.co/CULvYKvaaI, https://t.co/AaezGTp87r, https://t.co/YGftJ0SREC https://t.co/1LYWFpneIT
RT @CJ_Johnson17th: @_Nick_Diller Thank you YT link for those who use it I’m watching it now https://t.co/0nb4ZtXycx
RT @CJ_Johnson17th: @_Nick_Diller Thank you YT link for those who use it I’m watching it now https://t.co/0nb4ZtXycx
Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. https://t.co/ac8ThiUOzg
@_Nick_Diller Thank you YT link for those who use it I’m watching it now https://t.co/0nb4ZtXycx
Creatine, Peptides & Bioregulators: Separating Hype From Truth w/ Dr Wil... https://t.co/zRx9k43kUe via @YouTube
Creatine, Peptides & Bioregulators: Separating Hype From Truth w/ Dr Wil... https://t.co/8JDnGLXOBJ via @YouTube
@VSTRVL_FFF @objktcom gm...wats cookin??? Creatine, #Peptides & Bioregulators: Separating Hype From Truth w/ Dr William Seeds | Mind Pump 2667 https://t.co/97sSRgidlc #UFC #gymrat #thursdayvibes #digitalart #nft #silver #objkt4objkt #tezostuesday #art
LY vs NN 這場戰準備打到三收體合一世代了, 以後減肥藥隨便都這麼強啦 https://t.co/fdnbeSLptT https://t.co/3PK8zKoow2
@sukiyaki100kg レタトルチドに期待しております。 https://t.co/x3uwLERbJM
RT @Filip_Knop: Now in @NEJM
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
Retatrutide, a triple-hormone agonist, shows promise in obesity treatment! Phase 2 trial: up to 24.2% weight loss at 48 weeks vs 2.1% placebo. Higher doses yielded 83% of patients losing ≥15% weight. Mild GI side effects noted. #Obesity #ClinicalTrial https://t.co/aZySfosS5W
@RealRiddimHours @cremieuxrecueil 10 mg a week of Retatruitide! Yikes! No increase in effectiveness between 8 mg and 12 https://t.co/HTGV60oNPO
@bio_hacker_dao Behind the retatrutide? https://t.co/1rUJmbBqrE
@rn_flex @KNielsen2000 @GilaMonstrum Retatrutide is very effective @ WL but it’s clearly not their intended future. LLY is moving eventually to a quad agonist with GLP/GIP/DACRA based on their development pipeline (my original post) ARRHYTHMIAS were present in over 10% of the top 2 doses. https://t.co/cgmH24VwEC
Sources: SOURCE: JAMA 2023 Clinical Trial – https://t.co/7rjeSVFH5i SOURCE: NEJM 2023 – https://t.co/vWdbL4V25N SOURCE: Eli Lilly Retatrutide Pipeline Data – https://t.co/Rgw2adgq5o SOURCE: Nature Metabolism – https://t.co/lhJWVh5W84
@exfatloss @archived_videos @alex_etal Here’s the drug name https://t.co/kLPhYCZ9eG
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @StevenMathern: 'Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial', glp1a, gip, glucagon, glp-1, glp-1ra @BowTi…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
'Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial', glp1a, gip, glucagon, glp-1, glp-1ra @BowTiedHRT https://t.co/LQY3ZpsC48
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide…
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial #ERA25 In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight https://t.co/Yh0vGKq692 https://t.co/muHZgCtBpI
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
Links: https://t.co/Wv3JAMt4w3 https://t.co/fjiklKTrvc
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | New England Journal of Medicine https://t.co/9MclcrPrSw
@thanos_wasright @antidoc32 1mg is the minimum dose in the trials. I’m doing 1mg 2x per week with no side effects. The trials have gone as high as 12mg. https://t.co/agk9yq5R0z
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
RT @NefroClassMx: Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4%…
Medicamentos p obesidad Retatrutide –24.2% en 48 sem (83% ≥15%, –84% grasa hepática) CagriSema –22.7% en 68 sem (40.4% ≥25%) Tirzepatida –20.9% en 72 sem (64% ≥15%) Retatrutide lidera en eficacia; Tirzepatida, la más accesible. @avelromanneph
@pissedautist https://t.co/1rUJmbASC6
RT @Susumu_Manabe: 肥満治療薬レタトルチド12mgの内服で、1年後の体重が24.2%減少する。偽薬投与では体重減少はわずか2.1％。338例の肥満成人を対象にした第二相臨床試験（二重盲検化無作為化比較試験）の結果。 https://t.co/ig5B3Iryz…
RT @EricTopol: Not every day you see an anti-obesity drug that has an average of >24% body weight loss
In the retatrutide trials I see no mention at all of lean mass at all. Phase 2 obesity: https://t.co/7EoR47FhbL Meta-analysis of trials: https://t.co/l8E5FwKjPz A lot of this seems to be centered on the Glucagon MOA, but it's entirely speculative imo.
https://t.co/fD3D2XfqXh
RT @cremieuxrecueil: Unfortunately, it likely won't be available for prescription in the U.S. until 2026 or 2027. Sources: https://t.co/u…
RT @cremieuxrecueil: Unfortunately, it likely won't be available for prescription in the U.S. until 2026 or 2027. Sources: https://t.co/u…
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | New England Journal of Medicine https://t.co/DydSGzfyzm.
RT @cremieuxrecueil: Unfortunately, it likely won't be available for prescription in the U.S. until 2026 or 2027. Sources: https://t.co/u…
RT @cremieuxrecueil: Unfortunately, it likely won't be available for prescription in the U.S. until 2026 or 2027. Sources: https://t.co/u…
RT @cremieuxrecueil: Unfortunately, it likely won't be available for prescription in the U.S. until 2026 or 2027. Sources: https://t.co/u…
RT @cremieuxrecueil: Unfortunately, it likely won't be available for prescription in the U.S. until 2026 or 2027. Sources: https://t.co/u…
RT @cremieuxrecueil: Unfortunately, it likely won't be available for prescription in the U.S. until 2026 or 2027. Sources: https://t.co/u…
RT @cremieuxrecueil: Unfortunately, it likely won't be available for prescription in the U.S. until 2026 or 2027. Sources: https://t.co/u…
RT @cremieuxrecueil: Unfortunately, it likely won't be available for prescription in the U.S. until 2026 or 2027. Sources: https://t.co/u…
Unfortunately, it likely won't be available for prescription in the U.S. until 2026 or 2027. Sources: https://t.co/uJ4iDywoXS https://t.co/TnCvBmiB9K
@JayCampbell333 https://t.co/b5Rvhwrn60
Retatrutide vs. Ozempic Fascinating read in link below. https://t.co/H3ooXR01bF TLDR; Retatrutide, a triple-receptor agonist (GLP-1, GIP, glucagon), is showing greater weight loss than Ozempic (semaglutide). •Weight Loss: Retatrutide (24% reduction) vs. Ozempic (~15%)
@AlbertAppleyard @MWeintraubMD Here ya go! :) https://t.co/0wEI851Z5K
Retatrutide is a game changer and as per the standard bro science is far ahead of the so called scientific community. This drug is a game changer not just in obesity but addiction and overall sense of wellbeing. https://t.co/m78AMvz9hi Get yours at Elite Research
RT @RackMada: איבוד של מסת השריר, איבוד של מסת השלד ואוסטאופורוזיס. מי שרוצה לקרוא עוד יש פה סקירה מרתקת: https://t.co/6cCWfySQB6 ומאמר הנ…
איבוד של מסת השריר, איבוד של מסת השלד ואוסטאופורוזיס. מי שרוצה לקרוא עוד יש פה סקירה מרתקת: https://t.co/6cCWfySQB6 ומאמר הניסוי הקליני: https://t.co/UD1KGQCvbv
Sources: New obesity drugs - https://t.co/DkkRTtMaDr Triple agonist Retatrutide phase 2 trial - https://t.co/9YSBz304Lc
https://t.co/srmH4GFIaG https://t.co/u9aWr9f4kj https://t.co/iBISpBGwPu https://t.co/PT2akeeUMz https://t.co/iWAZ0kBFeA https://t.co/8FmCIoCHf9 https://t.co/1PFl9qfxNI https://t.co/DZmCeooT0G https://t.co/OZW1oM2nBL https://t.co/8FmCIoCHf9
RT @Susumu_Manabe: 肥満治療薬レタトルチド12mgの内服で、1年後の体重が24.2%減少する。偽薬投与では体重減少はわずか2.1％。338例の肥満成人を対象にした第二相臨床試験（二重盲検化無作為化比較試験）の結果。 https://t.co/ig5B3Iryz…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial Retatrutide (LY3437943) is an agonist of the…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial Retatrutide (LY3437943) is an agonist of the…
RT @drbennisahmed: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial Retatrutide (LY3437943) is an agonist of the…
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors substantiel reductions in body weight https://t.co/XEA9hv87A4 https://t.co/zfO5tJwioz
RT @ApoSpecialtyRx: Triple–Hormone-Receptor Agonist #Retatrutide for #Obesity -A Phase 2 Trial #Mounjaro #RanchoPalosVerdes #BeverlyHills…
Triple–Hormone-Receptor Agonist #Retatrutide for #Obesity -A Phase 2 Trial #Mounjaro #RanchoPalosVerdes #BeverlyHills #SantaBarbara #SantaMonica #NewportBeach #Manhattan #SiliconValley #Malibu #RanchoBernardo #NewYorkCity #NYC #Zepbound #Wegovy #Ozempic #SanFrancisco #Hollywood https://t.co/ttVERipyDp
RT @paulb3rd: Retatrutide - The Miracle Fat Loss Drug? https://t.co/kC0whI58iH via @YouTube
Retatrutide - The Miracle Fat Loss Drug? https://t.co/kC0whI58iH via @YouTube
Retatrutide - The Miracle Fat Loss Drug? https://t.co/4qj1i0NLMi via @YouTube #NAFLD #health #bodybuilding https://t.co/cboIIFKXGw
@Maroxad @DrNadolsky I'm on it for one of the phase 3 clinical trials and I'm not kidding it's gonna change medicine forever There's been multiple phase 2 studies published on it. This is the study that grabbed headlines: https://t.co/rvj9d1ZWPY
https://t.co/tVXDOF6SaN
@DRay0013 Correct and the results keep coming https://t.co/uViCGDxKGY
@allicovington Alli, I know you’re not being an ass ! https://t.co/uViCGDxKGY
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | New England Journal of Medicine https://t.co/Ur4j2GPVOk
https://t.co/MQ5d8YxYox رابط المقال
@CedricAPhillips I mean by modern medicine standards it is pretty miraculous… highly effective drug for intended effects with minimal negative side effects. And they have been working on versions more targeted for the weight loss effects that should be even more effective https://t.co/B7GbhZCZAV
@Pharmdca @pharmdca has Viking published their Phase 2 anywhere in a peer reviewed journal or just made a company announcement? https://t.co/LDimLB7lQy
@Glp1Insider Did you review the SAEs on the Phase 2? I’ll wait until we get Phase 3 data so we can understand what is happening with reports of arrhythmia. https://t.co/afzYb9tK7U
El paradigma de disminuir lípidos para prevención cardiovascular ha servido para vender estatinas. Ahora que se dispone de la terapia Triple G que es más costosa quizás se cambie el paradigma a la insulinoresistencia https://t.co/5C4YCugo2X
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial - https://t.co/D01l8tcN1p https://t.co/3puxBM3OP8
Retatrutide, the new triple agonist Ozempic upgrade, works by increasing Glucagon in the system, which signals ketone production! I suspect it will be very helpful at inducing ketosis! Strong combo for fat loss. Potential risks
I closely watching this @EliLillyandCo drug https://t.co/V3MghnXd8m
Number 1 Top Cardiometabolic Story of 2023: Phase 2 trial with #retatrutide, a GIP-GLP-1-GCG receptor triple agonist, resulted in a mean weight reduction of 24.2% after 48 weeks. https://t.co/JGjt8ryVtP
RT @scottisaacsmd: Number 1 Top Cardiometabolic Story of 2023: Phase 2 trial with #retatrutide, a GIP-GLP-1-GCG receptor triple agonist, r…
RT @scottisaacsmd: Number 1 Top Cardiometabolic Story of 2023: Phase 2 trial with #retatrutide, a GIP-GLP-1-GCG receptor triple agonist, r…
@ruth_hook_ Didn’t know we had triple hormone receptor agonist ( GLP-1, GIP, and glucagon receptors) out yet. I’d bet high protein with resistance training would get you better body composition with these [https://t.co/Akh84fMgn0 [https://t.co/Pl5p01i1fi https://t.co/gDJMsqnd5m
@emily_fri In P2 two highest doses averaged 24% body weight loss but were STILL losing at 48 weeks. It also reduced A1C, triglycerides, cholesterol, BP and resolved NAFLD in that P2 trial. I'm of the mind this drug will far more of a game changer than Wegovy https://t.co/rvj9d1ZWPY
@cdekatz Trial is is year and 7 months long so I've got 11 months to go. It's phase 3. Phase 2 results here: https://t.co/rvj9d1ZWPY
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial https://t.co/jNL1GNnHPT #Endocrinology https://t.co/ZknpCo49ky
Em julho de 2023, no Congresso da American Diabetes Association, foi apresentado um estudo de fase 2 com a Retatrutida que trouxe resultados de impacto no tratamento da obesidade. https://t.co/iM4qLboNkb
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @NEJM: This week’s most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Tria…
RT @SeeFisch: I THINK THIS ONE WILL BE A WINNER AND WILL DE-MAP (make obsolete) semaglutide (ozempic) Triple-Hormone-Receptor Agonist Ret…
I THINK THIS ONE WILL BE A WINNER AND WILL DE-MAP (make obsolete) semaglutide (ozempic) Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial https://t.co/eDlGjHDObp
GLP-1アゴニストから、 トリアゴニスト開発へヒートアップ！？ https://t.co/wO1tGsHwjN https://t.co/sYM51UOn3M
RT @mendesthiagob: ❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated signifi…
RT @mendesthiagob: ❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated signifi…
RT @mendesthiagob: ❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated signifi…
RT @mendesthiagob: ❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated signifi…
RT @mendesthiagob: ❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated signifi…
RT @mendesthiagob: ❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated signifi…
RT @mendesthiagob: ❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated signifi…
RT @mendesthiagob: ❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated signifi…
RT @mendesthiagob: ❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated signifi…
https://t.co/8PuTN1qRnh New era in the treatment of obesity. Triple G-agonist #endocrinology #metabolism #obesity #EndoTwitter #MedTwitter
RT @mendesthiagob: ❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated signifi…
RT @mendesthiagob: ❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated signifi…
❗️GLP-1 RA has transformed obesity treatment ‼️Combination therapy (GLP-1 RA and GIP agonists) has demonstrated significant advancement
RT @YLeyfman: In a phase 2, double-blind, randomized, placebo-controlled trial utilizing Retatrutide, a GLP-1 agonist, in adults with BMI 3…
In a phase 2, double-blind, randomized, placebo-controlled trial utilizing Retatrutide, a GLP-1 agonist, in adults with BMI 30+ demonstrated a weight reduction of 5-15% by 48 weeks. The most common adverse events were GI-related. https://t.co/gMEcI7ffo4
This seems almost unreal!! Retatrutide for Obesity —from @NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2301972?query=featured_home
RT @dr_ukio: 【トリプルGアゴニストの非DM肥満への効果（NEJM)】 GIP/GLP-1/グルカゴンのトリプルGアゴニスト（レタトルチド）第2相試験、非DM肥満（BMI 27以上）338人。48週後体重はプラセボ-2.1％、1mg-8.7％、4mg-17.1％、…
RT @dr_ukio: 【トリプルGアゴニストの非DM肥満への効果（NEJM)】 GIP/GLP-1/グルカゴンのトリプルGアゴニスト（レタトルチド）第2相試験、非DM肥満（BMI 27以上）338人。48週後体重はプラセボ-2.1％、1mg-8.7％、4mg-17.1％、…
RT @dr_ukio: 【トリプルGアゴニストの非DM肥満への効果（NEJM)】 GIP/GLP-1/グルカゴンのトリプルGアゴニスト（レタトルチド）第2相試験、非DM肥満（BMI 27以上）338人。48週後体重はプラセボ-2.1％、1mg-8.7％、4mg-17.1％、…
【トリプルGアゴニストの非DM肥満への効果（NEJM)】 GIP/GLP-1/グルカゴンのトリプルGアゴニスト（レタトルチド）第2相試験、非DM肥満（BMI 27以上）338人。48週後体重はプラセボ-2.1％、1mg-8.7％、4mg-17.1％、8mg-22.8％、12mg-24.2％。 https://t.co/bGahqimjcM https://t.co/XUVDiooWQI
https://t.co/5FbGH0lfeF
RT @pzjarana: Si pensáis que todo había acabado con el GLP1 (Ozempic o Saxenda), vais a flipar con el retatrutide. GLP1 + GIP + Glucagón…
RT @pzjarana: Si pensáis que todo había acabado con el GLP1 (Ozempic o Saxenda), vais a flipar con el retatrutide. GLP1 + GIP + Glucagón…
RT @pzjarana: Si pensáis que todo había acabado con el GLP1 (Ozempic o Saxenda), vais a flipar con el retatrutide. GLP1 + GIP + Glucagón…
RT @pzjarana: Si pensáis que todo había acabado con el GLP1 (Ozempic o Saxenda), vais a flipar con el retatrutide. GLP1 + GIP + Glucagón…
RT @pzjarana: Si pensáis que todo había acabado con el GLP1 (Ozempic o Saxenda), vais a flipar con el retatrutide. GLP1 + GIP + Glucagón…
RT @pzjarana: Si pensáis que todo había acabado con el GLP1 (Ozempic o Saxenda), vais a flipar con el retatrutide. GLP1 + GIP + Glucagón…
Si pensáis que todo había acabado con el GLP1 (Ozempic o Saxenda), vais a flipar con el retatrutide. GLP1 + GIP + Glucagón Pérdidas de casi el 25% del peso inicial en menos de un año. Esto es casi lo que se pierde con cirugía bariátrica
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial https://t.co/w63ZRYWuA5
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
While LMICs are starving, the western world exults for spending in anti-obesity drugs without sacrificing the western diet. https://t.co/5rwKQyoZ9J
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
RT @RobertoBurioni: Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettia…
Ottime notizie. Un nuovo farmaco, la retatrutide, sembra avere un'ottima efficacia nel combattere l'obesità. Aspettiamo la fine della fase 3, i risultati preliminari sono però ottimi, con la dose massima i pazienti hanno perso il 25% del loro peso. https://t.co/pVRzXRoG80
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM https://t.co/vkW9wyNstj
Bibliografia en @PubMedOnline Jastreboff AM et al. Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972. https://t.co/PndOm3S16m
Full text links @NEJM Jastreboff AM et al Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972. https://t.co/s987sa46Uh
RT @martijnkatan: De nieuwste 'tide’ is alweer effectiever: dikke mensen vielen in 1 jaar 25 kg af. https://t.co/9q8eQWQgw3 Na 3 jaar wordt…
necesito entrar en algún ensayo clínico de esto.... Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM https://t.co/4lGaJBj40M
Treatment with retatrutide allowed to lose up to 24% of baseline weight at 48 weeks in #overweight and #obesity patients #VisualAbstract https://t.co/lHma2X9leE https://t.co/P9JbUXMo6f
RT @ObesitySeen: Publicados los dos ensayos fase 2 de retatrutide en diabetes https://t.co/h6u5ErnFZi y obesidad https://t.co/ON461hky9L co…
From #ADA2023 | @EliLillyandCo presented study results of their investigational therapies that show promise to deliver breakthrough outcomes across the spectrum of care for T2D and obesity. Learn more in @NEJM https://t.co/CEQ1f72DFJ and @TheLancet https://t.co/0mhvqB6xB8 https://t.co/EIWByyREb9
RT @martijnkatan: De nieuwste 'tide’ is alweer effectiever: dikke mensen vielen in 1 jaar 25 kg af. https://t.co/9q8eQWQgw3 Na 3 jaar wordt…
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial https://t.co/PFZaistA6d
RT @MMadkhali87: https://t.co/6NQbCeYJiH
RT @tjstokes5: Intriguing data showing the rather dramatic effects of Retatrutide on weight loss in obese participants: https://t.co/hqnFOs…
https://t.co/e4zLyvxjnC
Publicados los dos ensayos fase 2 de retatrutide en diabetes https://t.co/h6u5ErnFZi y obesidad https://t.co/ON461hky9L con resultados muy esperanzadores!
في البالغين المصابين بالسمنة ، Retatrutide. أدى العلاج لمدة 48 أسبوعًا إلى انخفاض كبير في وزن الجسم. (بتمويل من Eli Lilly ؛ رقم https://t.co/zeFX9OVpqo ، NCT04881760. يفتح في علامة تبويب جديدة.) https://t.co/lKoZyZyV93
RT @NeilFlochMD: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | @NEJM #obesity https://t.co/Z8vHZs3UoQ
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | @NEJM #obesity https://t.co/Z8vHZs3UoQ
Intriguing data showing the rather dramatic effects of Retatrutide on weight loss in obese participants: https://t.co/hqnFOsEcsB Given the degree of weight loss, it'd be interesting to know how well lean tissue mass is preserved
https://t.co/RpHwR4G0Se
RT @ConscienHealth: Results published today in @NEJM 5/ https://t.co/XoIlE2jePM
The Phase 2 trial results were published in @NEJM. @EliLillyandCo now plans a comprehensive Phase 3 program evaluating once-weekly injectable #retatrutide in chronic weight management as well as addressing various complications of obesity. https://t.co/CudZYiQtcH
RT @ConscienHealth: Results published today in @NEJM 5/ https://t.co/XoIlE2jePM
The paper on 'Retatrutide' in "NEJM" the "Nature" is partly based upon, & links to: “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial” 3/3 https://t.co/LnE5yluum4
https://t.co/6NQbCeYJiH
@ChristianAssad @AniaJastreboff @EliLillyandCo https://t.co/Mo34DftG0D
RT @martijnkatan: De nieuwste 'tide’ is alweer effectiever: dikke mensen vielen in 1 jaar 25 kg af. https://t.co/9q8eQWQgw3 Na 3 jaar wordt…
De nieuwste 'tide’ is alweer effectiever: dikke mensen vielen in 1 jaar 25 kg af. https://t.co/9q8eQWQgw3 Na 3 jaar wordt dat denk ik 30 kg. https://t.co/vHr361aWFH Kledingfabrikanten, ziekenhuizen en pensioenfondsen, bereid je maar voor: over 15 jaar is obesitas grotendeels weg.
RT @96hage: 体重減少薬が花盛りです 太っている人の体重がEli Lillyの3受容体活性化剤retatrutide（レタトルチド、LY3437943）で48週間後に多ければ24.2%減 https://t.co/ovWSHRMxAF
体重減少薬が花盛りです 太っている人の体重がEli Lillyの3受容体活性化剤retatrutide（レタトルチド、LY3437943）で48週間後に多ければ24.2%減 https://t.co/ovWSHRMxAF
100% of patients with obesity or BMI 27-30 with additional condition lost at least 5% of body weight at top dose. Weight loss medicine and cardiovascular medicine are going hand in hand as we work to lead treatments for cardiometabolic disease. https://t.co/uoBCN7yRGu
Results published today in @NEJM 5/ https://t.co/XoIlE2jePM
ら
WL
RF
R